Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Forecast for the Central Nervous System (CNS) Lymphoma Market Growth in 2025?
The market for central nervous system (CNS) lymphoma has seen considerable growth in recent years. The market size is projected to expand from $1.44 billion in 2024 to an estimated $1.54 billion in 2025, with a compound annual growth rate (CAGR) of 7.0%. The growth during the historical period may be attributed to factors such as heightened awareness and diagnosis, escalating lymphoma incident rates, an increasing number of clinical trials, enhanced funding for cancer research, and the increased utilization of biomarkers for tailored treatments.
What Is the Forecast for the Central Nervous System (CNS) Lymphoma Market Size Through 2029?
In the coming years, the market size for central nervous system (CNS) lymphoma is predicted to witness robust growth. The market is anticipated to expand to a value of $1.99 billion by 2029, progressing at a compound annual growth rate (CAGR) of 6.6%. The significant growth anticipated during the forecast period can be attributed to factors such as the increasing acceptance of immunotherapy, greater emphasis on targeted treatments, a rise in the incidence of CNS lymphoma, enhanced patient healthcare accessibility, as well as government backing and initiatives. Forecast period trends are expected to encompass the incorporation of artificial intelligence in diagnostics, the production of next-generation monoclonal antibodies, a shift toward less invasive procedures, advancements in precision medicine, and progress in diagnostic technology capabilities.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21133&type=smp
What are the Key Market Players in Central Nervous System (CNS) Lymphoma Market and How They’re Evolving?
Major companies operating in the central nervous system (CNS) lymphoma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Incyte Corporation, ONO PHARMA USA Inc., Kazia Therapeutics Limited, Simcere Pharmaceutical Group Limited, Karyopharm Therapeutics Inc., Nurix Therapeutics Inc., CNS Pharmaceuticals Inc., JW Therapeutics, PentixaPharm Pty Ltd, Cellectar Biosciences Inc.
What Are the Primary Growth Drivers in the Central Nervous System (CNS) Lymphoma Market?
The central nervous system (CNS) lymphoma market is predicted to see a surge due to the growing cases of psychological disorders. These mental health conditions interfere with thoughts, feelings, or actions, leading to distress or dysfunction. Factors like stress, social isolation, economic issues, hereditary influences, substance misuse, and excessive digital use contribute significantly towards the rise in psychological disorders. CNS lymphoma, which promotes neuro-oncology research, augments the understanding of brain inflammation, immune reactions, and the blood-brain barrier, all of which help evolve superior treatments for both cancer and psychological disorders. For instance, the National Alliance On Mental Illness, a US-based organization, disclosed in 2024 that nearly 600,000 hospitalizations each year among U.S. residents aged 18-44 are attributed to psychosis spectrum and mood disorders. Hence, the escalating instances of psychological disorders are propelling the growth of the CNS lymphoma market. Bringing attention to the upsurge in neurological disorders, it is suggested that this could also fuel the demand for the CNS lymphoma market. Neurological disorders, referring to conditions impacting the nervous system, including the brain, spinal cord, and nerves, have seen a rise due to reasons like genetic predisposition, infections, injury, toxins, auto-immune reactions, and deterioration. CNS lymphoma supports research into brain function, immune responses, and neuroinflammation, thereby enhancing diagnostics and treatments that aid patients with neurological disorders. An April 2022 report by the European Brain Council, a Belgium-based non-profit organization, states that over 600 neurological diseases and close to 300 psychiatric conditions affect millions worldwide, including 65 million suffering from epilepsy. In Europe, 10.5 million people have dementia, with the number predicted to rise to 18.7 million by 2050. Consequently, the increasing occurrence of neurological disorders predicts a propelling growth for the CNS lymphoma market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21133&type=smp
What Are the Leading Segments in the Global Central Nervous System (CNS) Lymphoma Industry?
The central nervous system (CNS) lymphoma market covered in this report is segmented –
1) By Class Of Drugs: Monoclonal antibodies, Chemotherapeutic Agents, Corticosteroids
2) By Treatment: Chemotherapy, Radiation Therapy, Steroid Therapy, Targeted Therapy
3) By Application: Hospitals, Clinics, Ambulatory Surgical Services, Other Applications
Subsegments:
1) By Monoclonal Antibodies: Anti-CD20 Monoclonal Antibodies, Anti-PD-1 Monoclonal Antibodies, Other Targeted Monoclonal Antibodies
2) By Chemotherapeutic Agents: Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors
3) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone
What Are the Key Market Trends in the Central Nervous System (CNS) Lymphoma Industry?
Key businesses in the central nervous system (CNS) lymphoma market are concentrating on the development of novel treatments, for example, Tirabrutinib, for primary central nervous system (CNS) lymphoma. Tirabrutinib has been developed as an extremely selective Bruton’s tyrosine kinase (BTK) inhibitor intended to treat B-cell malignancies including primary central nervous system lymphoma (PCNSL) by targeting key pathways for the survival and multiplication of the cancer cells. For instance, in March 2023, tirabrutinib (ONO-4059) was given orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of primary central nervous system lymphoma (PCNSL) as announced by the US-based pharmaceutical company, ONO Pharma Inc. Currently, it is under examination in the phase 2 PROSPECT study (NCT04947319), with tirabrutinib acting as a potent, selective BTK inhibitor that targets B-cell survival and proliferation. Tirabrutinib controls cell proliferation and activation through the B-cell receptor, facilitating B-cells survival, differentiation, and clonal expansion.
Access The Full Report Here:
What Is the Regional Outlook for the Central Nervous System (CNS) Lymphoma Market?
North America was the largest region in the central nervous system (CNS) lymphoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system (CNS) lymphoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21133
This Report Delivers Insight On:
1. How big is the central nervous system (cns) lymphoma market, and how is it changing globally?
2. Who are the major companies in the central nervous system (cns) lymphoma market, and how are they performing?
3. What are the key opportunities and risks in the central nervous system (cns) lymphoma market right now?
4. Which products or customer segments are growing the most in the central nervous system (cns) lymphoma market?
5. What factors are helping or slowing down the growth of the central nervous system (cns) lymphoma market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model